Edward B Garon Selected Research

Pemetrexed (MTA)

10/2023	Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
9/2023	Corrigendum to "Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189" [Lung Cancer 155 (2021) 53-60].
12/2022	Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
1/2022	Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.
1/2021	Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
1/2021	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
10/2020	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
1/2020	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
1/2019	Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
5/2015	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward B Garon Research Topics

Disease

103	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 07/2010
66	Neoplasms (Cancer) 03/2024 - 08/2007
24	Disease Progression 11/2023 - 02/2012
21	Lung Neoplasms (Lung Cancer) 10/2023 - 05/2011
6	Fatigue 01/2021 - 08/2014
5	Melanoma (Melanoma, Malignant) 01/2024 - 01/2017
5	Neoplasm Metastasis (Metastasis) 10/2021 - 12/2012
4	Pneumonia (Pneumonitis) 03/2023 - 01/2018
4	Circulating Neoplastic Cells 01/2020 - 06/2012
4	Hypertension (High Blood Pressure) 01/2020 - 08/2014
3	Dyspnea (Shortness of Breath) 12/2023 - 10/2020
3	Cough 01/2023 - 01/2020
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 06/2012
3	Febrile Neutropenia 01/2020 - 08/2014
3	Adenocarcinoma 01/2018 - 10/2012
2	Diarrhea 12/2023 - 01/2017
2	Pain (Aches) 12/2023 - 10/2020
2	Pneumothorax 11/2021 - 12/2019
2	Brain Neoplasms (Brain Tumor) 08/2021 - 10/2020
2	Carcinogenesis 04/2021 - 01/2021
2	Neutropenia 01/2020 - 08/2014
2	Thrombocytopenia (Thrombopenia) 11/2019 - 06/2012
2	Breast Neoplasms (Breast Cancer) 01/2015 - 07/2010
1	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2023
1	Hemoptysis 12/2023
1	Constipation 12/2023
1	Vomiting 12/2023
1	Nausea 12/2023
1	Thrombosis (Thrombus) 10/2023
1	Mesothelioma 01/2022
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Residual Neoplasm 01/2022
1	Hypoxia (Hypoxemia) 01/2021

Drug/Important Bio-Agent (IBA)

32	pembrolizumabIBA 01/2024 - 04/2015
22	Biomarkers (Surrogate Marker)IBA 02/2023 - 02/2012
20	RamucirumabIBA 01/2023 - 11/2012
18	PlatinumIBA 10/2023 - 11/2012
16	Immune Checkpoint InhibitorsIBA 01/2024 - 04/2015
16	Docetaxel (Taxotere)FDA Link 01/2023 - 11/2012
13	Pemetrexed (MTA)FDA Link 10/2023 - 10/2013
13	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2023 - 11/2011
12	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2011
10	B7-H1 AntigenIBA 01/2023 - 05/2018
8	durvalumabIBA 03/2024 - 01/2020
8	Tyrosine Kinase InhibitorsIBA 10/2021 - 01/2013
8	LigandsIBA 08/2021 - 01/2018
7	Carboplatin (JM8)FDA LinkGeneric 10/2023 - 10/2013
7	NivolumabIBA 01/2023 - 10/2015
6	tremelimumabIBA 03/2024 - 01/2020
6	Bevacizumab (Avastin)FDA Link 10/2017 - 11/2012
5	Monoclonal AntibodiesIBA 03/2020 - 01/2017
4	Proteins (Proteins, Gene)FDA Link 04/2021 - 02/2012
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 12/2013
3	Cisplatin (Platino)FDA LinkGeneric 10/2023 - 10/2013
3	osimertinibIBA 03/2023 - 01/2021
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 12/2019
3	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2020
3	Immunoglobulins (Immunoglobulin)IBA 03/2020 - 10/2017
3	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 01/2019 - 06/2013
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2013 - 07/2010
2	InterleukinsIBA 10/2023 - 03/2020
2	canakinumab FDA Link 10/2023 - 03/2020
2	capmatinibIBA 01/2023 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2022
2	Circulating Tumor DNAIBA 12/2022 - 01/2020
2	VaccinesIBA 12/2022 - 11/2020
2	Aromatase (CYP19)IBA 04/2021 - 12/2012
2	Peptides (Polypeptides)IBA 12/2020 - 06/2012
2	dacomitinibIBA 05/2019 - 01/2017
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2019 - 06/2013
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 03/2016
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2018 - 03/2013
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 10/2017
2	Fulvestrant (Faslodex)FDA Link 01/2018 - 03/2013
2	CrizotinibIBA 01/2018 - 02/2015
2	Epidermal Growth Factor (EGF)IBA 12/2017 - 01/2015
2	Estrogen ReceptorsIBA 01/2015 - 03/2013
1	Immunoconjugates (Immunoconjugate)IBA 10/2023
1	Surface Antigens (Surface Antigen)IBA 10/2023
1	SteroidsIBA 03/2023
1	Temozolomide (Temodar)FDA LinkGeneric 01/2023
1	cyclopropapyrroloindoleIBA 01/2023
1	mocetinostatIBA 01/2023
1	Histone Deacetylase InhibitorsIBA 01/2023
1	lenvatinibIBA 01/2023
1	ChemokinesIBA 01/2023
1	atezolizumabIBA 01/2023
1	DV281IBA 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2020
1	Glutamic Acid (Glutamate)FDA Link 12/2020

Therapy/Procedure

43	Therapeutics 03/2024 - 08/2007
30	Drug Therapy (Chemotherapy) 03/2024 - 09/2012
17	Immunotherapy 01/2023 - 10/2015
6	Radiotherapy 01/2024 - 10/2013
2	Retreatment 11/2020 - 10/2020
1	Aftercare (After-Treatment) 11/2023
1	Chemoradiotherapy 02/2023
1	Neoadjuvant Therapy 01/2023
1	Injections 11/2021
1	Chest Tubes (Chest Tube) 11/2021